What's on your mind?

There's both much to know and much to say and we'd like to hear from you; your ideas, your experiences... anything that helps provide perspective on lives that have been impacted by diseases of the central nervous system.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
March 21, 2023

Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

Boston, MA – March 21, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.

  • 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
  • Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28in Cambridge, UK

7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets Conference

Presentation Details

Title: Identification of THIK-1 as a therapeutic target for neuroinflammatory diseases: Discovery and characterisation of a selective THIK-1 blocker

Overview: The NETSseq platform can identify unexplored and druggable microglia targets, exemplified by THIK-1, as potential therapies for neurodegenerative diseases. The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored.

Presenter: Anna Rowland, PhD

Session Date and Time: March 27, 2023, 1:30-2:45pm

Binding Kinetics and Mechanistic PK/PD Modelingin Early Drug Discovery Conference

Poster Details

Title :Analysis of the Initial Velocity of Calcium Signalling and β-Arrestin Recruitment at GPR55 with Different Activators ShowsUnique Signalling Profiles

Overview: Three proprietary small molecule activators of GPR55 display unique signalling profiles when measuring the initial velocity of calcium and β-arrestin pathway activation.

Presenter: Philip Pickford

Poster Number: 10

About Cerevance

Cerevanceis a private pharmaceutical company with a focus on CNS disorders. CVN424,Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergiccompound acting on a novel target (GPR6), that demonstrated significant andclinically meaningful efficacy in a 136-patient Phase 2 study in patients withParkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq)platform to identify highly selectively expressed, novel target proteins thatare either specific to certain brain circuits or are over- or under-expressedin diseased brains. Partnering with over 25 brain banks and evaluating anexpanding collection of more than 12,000 human post-mortem brain tissuesamples, Cerevance is advancing a robust pipeline of targeted treatments forpatients with neurodegenerative diseases, including Parkinson’s disease,Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit www.cerevance.com.



Johnna Simoes, ir@cerevance.com


Andrew Mielach, amielach@lifescicomms.com, +1-646-876-5868